Myocardial phosphoproteomics and single cardiomyocyte force measurements endorse DYRK1A as a candidate therapeutic target for incomplete reverse remodelling after aortic valve replacement

20 May 2023 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in basic science 2 Cardiac Diseases HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

ESC 365 is supported by

ESC 365 is supported by